Newswise — BOSTON – July 1, 2014 – Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs –small RNA molecules that play important roles in regulation in many types of tissue – play a major role in the distribution and determination of fat cells and whole body metabolism. Also, the study is the first to reveal that microRNAs (miRNAs) influence the development of lipodystrophy (abnormal fat accumulation) which affects many people with HIV receiving anti-retroviral therapy. The findings appear in the August issue of the Journal of Clinical Investigation.
Previous Joslin studies have demonstrated that fat cells (adipocytes) have functions far beyond fat storage: they secrete substances that actively influence metabolism and are also a site of systemic inflammation leading to insulin resistance. The body has two types of fat – the more common white adipose fat (WAT), which stores fat; and brown adipose fat (BAT), which burns fat to produce heat. BAT plays a beneficial role in regulating body weight and metabolism, which has generated considerable interest among scientists and pharmaceutical companies looking for treatments for obesity. Excess WAT, on the other hand, especially in the intra-abdominal area, is associated with metabolic diseases, such as type 2 diabetes.
In the current study, Joslin scientists were interested in learning more about miRNAs and their role in the creation of fat cells and the function of brown and white fat. Earlier Joslin research revealed that with aging, miRNA processing in fat tissue decreases due to a decrease in Dicer, a critical enzyme that converts pre-miRNAs to mature miRNAs.
Using a mouse model in which expression of Dicer was specifically knocked out in fat tissue, the researchers found that mice that lacked Dicer in fat developed abnormal fat distribution resembling HIV-related lipodystrophy (which is associated with antiviral treatment). In mice, this form of lipodystrophy was also characterized by “whitening” of brown fat cells, a loss of white fat, and signs of metabolic syndrome, including insulin resistance, fat tissue inflammation, dyslipidemia (elevated cholesterol and fat), increased resting energy use, and increased markers of cardiovascular disease.
The researchers also found lower Dicer levels in the fat tissue of patients with HIV and HIV-related lipodystrophy, suggesting that low levels of Dicer expression in fat in HIV patients may contribute to the development of this syndrome, a complication which limits therapy in some people with HIV.
Together, these findings indicate an essential role for Dicer and miRNA processing in white and brown cell differentiation and whole body metabolism that may contribute to the development of HIV-related lipodystrophy. “It’s good to build on our previous research on miRNA processing and Dicer in aging and find that a decline in Dicer may also play an important role in HIV lipodystrophy by dramatically changing the biology of fat and the tendency towards diabetes and metabolic syndrome,” says lead author C. Ronald Kahn, MD, Chief Academic Officer at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. “This research is a good example of how we go from the “bench” to the bedside and how discoveries in one area or research can lead to insights into other clinical disorders.”
This research suggests that therapy with an agent that increases levels of Dicer or specific miRNA expression could be beneficial to people with metabolic syndrome. “If we could increase Dicer activity, fat tissue would have a healthier metabolism which would improve the metabolism of people being treated. It may also reduce the effects of changes in fat that cause insulin resistance and other symptoms of metabolic diseases, such as diabetes,” Dr. Kahn says.
Dicer-related therapy might also help patients with HIV-related lipodystrophy. “In some people with HIV, lipodystrophy is so disfiguring that they alter or stop HIV therapy. If we could address the abnormal fat accumulation, people could continue their HIV therapies and get maximal benefit,” Dr. Kahn says.
One possible agent that might increase Dicer levels is Rapamycin, an immunosuppressant used to prevent rejection in organ transplantation. Dr. Kahn and Joslin researchers are planning to investigate whether Rapamycin increases Dicer in cellular models.
The Joslin researchers are currently conducting related research to:
• Learn whether changes in fat tissue alter liver metabolism and muscle tissue and the mechanism that communicates these changes.
• Determine if miRNAs can serve as therapeutic agents to treat diseases by identifying miRNAs that are deficient and restoring them to normal levels.
Study co-authors include Marcelo A. Mori, Thomas Thomou, Jeremie Boucher, Kevin Y. Lee, Graham Smyth, Michael Rourk and Aaron M. Cypess of Joslin; Susanna Lallukka and Hannele Yki-Järvinen of the University of Helsinki; Jason K. Kim of the University of Massachusetts Medical School; and Martin Torriani and Steven K. Grinspoon of Massachusetts General Hospital and Harvard Medical School.
Funding for the study was provided by the National Institutes of Health, the Ellison Foundation, the Joslin Diabetes and Endocrine Research Center, the Academy of Finland, the Sigrid Juselius Foundation and FAPESP.
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
About Joslin Research
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty‐level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit www.joslinresearch.org.